Madrigal's Rezdiffra Soars in MASH Market as Novo Nordisk Enters the Arena

Madrigal Pharmaceuticals has reported a significant sales boost for its metabolic dysfunction-associated steatohepatitis (MASH) treatment, Rezdiffra, while welcoming new competition from pharmaceutical giant Novo Nordisk. The latest financial results and market developments signal a promising future for MASH treatments and increased awareness of this underdiagnosed condition.

Rezdiffra's Impressive Growth

Madrigal's Rezdiffra, the world's first treatment for MASH, generated sales of $287 million in the third quarter of 2025, marking a 35% sequential increase from the previous quarter. This performance puts the drug on track to surpass $1 billion in annualized sales, a remarkable achievement for a treatment in only its fifth full quarter on the market.

The company reported that 29,300 patients have been prescribed Rezdiffra through the third quarter, up from 23,000 in the previous period. Despite this growth, Madrigal sees considerable room for expansion within the targeted group of 315,000 patients diagnosed with fatty liver disease.

Market Expansion and Competition

Novo Nordisk recently received FDA approval for a label expansion of its GLP-1 agonist, Wegovy, to include MASH treatment. This development has been welcomed by Madrigal, with CEO Bill Sibold stating, "We welcome new entrants to this evolving market. Wegovy's recent approval in MASH adds momentum to a market that's just starting to take shape."

Madrigal believes that Novo Nordisk's entry will help increase the overall patient pool by raising awareness and driving more screening, diagnosis, and treatment. The company is not concerned about immediate competition, as Sibold explained, "What we're excited about is having somebody else that is going to help us carry the load of increasing diagnosis."

Strategic Marketing and Future Outlook

Both Madrigal and Novo Nordisk are targeting specific healthcare professional groups in their marketing efforts. Novo Nordisk is focusing on U.S. hematologists and gastroenterologists, while Madrigal has expanded its outreach to include endocrinologists.

Madrigal's share price has increased by 20% following the announcement of its quarterly results. The company also secured a new patent for Rezdiffra, extending its U.S. market protection until 2045. With $1.1 billion in cash and cash equivalents on hand, Madrigal appears well-positioned for continued growth and development in the MASH treatment market.